<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523315</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OKR-ARI-2007/1</org_study_id>
    <nct_id>NCT00523315</nct_id>
  </id_info>
  <brief_title>APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)</brief_title>
  <acronym>APOLLO</acronym>
  <official_title>A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in&#xD;
      the postmenopausal, early breast cancer as seen under current practice&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">862</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Department of Surgery or Department of Hemato-oncology in 36 hospitals&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
          -  Patients with early breast cancer who are scheduled to receive first-line adjuvant&#xD;
             endocrine therapy with aromatase inhibitor under the routine clinical practice&#xD;
&#xD;
          -  Histologically or cytologically proven to be HR+(ER or PR +)&#xD;
&#xD;
          -  Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by&#xD;
             the local guideline):&#xD;
&#xD;
               -  Age &gt;= 50 years&#xD;
&#xD;
               -  Age &lt; 50 years with amenorrhoea &gt; 12 months and an intact uterus&#xD;
&#xD;
               -  FSH levels within postmenopausal range (over 30-40 IU/ml), or&#xD;
&#xD;
               -  Having undergone a bilateral oophorectomy.&#xD;
&#xD;
               -  No other concomitant endocrine therapy such as estrogen therapy or selective&#xD;
                  estrogen receptor modulators&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurrence of breast cancer&#xD;
&#xD;
          -  Known hypersensitivity to aromatase inhibitor or to any of the excipients&#xD;
&#xD;
          -  Any severe concomitant condition which makes it undesirable for the patient to&#xD;
             participate in the trial or which would jeopardize compliance with the trial protocol&#xD;
&#xD;
          -  Previous inclusion in the present study&#xD;
&#xD;
          -  Participation in a clinical study during the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joon Woo Bahn</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheonan-si</city>
        <state>Chuncheongnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kangnung-si</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinju-si</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserach Site</name>
      <address>
        <city>Euijungbu-si</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iksan-si</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daejoen</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Democratic People's Republic of</country>
  </removed_countries>
  <link>
    <url>http://www.astrazeneca.com/node/emailtriage.aspx</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marketing Company Medical Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Aromatase Inhibitor</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>compliance</keyword>
  <keyword>Naturalistic</keyword>
  <keyword>Observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

